Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
State Street steps up push into secondaries as retail access expands
State Street steps up push into secondaries as retail access expands State Street is seeking to deepen its exposure to private markets secondaries as it looks to broaden access for retail investors, according to Yie-Hsin Hung, chief executive of State Street...
Hellman & Friedman tests $9bn-plus exit for medical device group Cordis
Hellman & Friedman tests $9bn-plus exit for medical device group Cordis Hellman & Friedman is weighing a potential sale of medical device company Cordis at a valuation of more than $9bn, in a move that could rank among the largest healthcare exits by a private...
Brookfield-backed Clean Max plans smaller $350m–$400m India IPO
Brookfield-backed Clean Max plans smaller $350m–$400m India IPO Brookfield-backed Clean Max Enviro Energy Solutions is preparing to revive its Indian IPO plans with a reduced offering of about $350m to $400m, as valuation pressures weigh on renewable energy listings....